Effects of DPP‐4 inhibitors, GLP‐1 receptor agonists, SGLT‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach
Authors' conclusion
The findings from our analyses substantiate the relevance of treatment with SGLT-2 inhibitors or GLP-1RAs as an add-on to metformin in patients with T2D and a high risk for cardiovascular disease, and furthermore, support the recommendation for SGLT-2 inhibitor treatment in patients with T2D and heart failure or established kidney disease.
Study context
- Population
- T2D populations at low and high CVD risk, incl. established CVD and/or kidney disease; metformin background therapy in the vast majority
- Comparison
- SGLT2i vs GLP-1 RA vs DPP-4i vs SU
- Outcome
- Mortality and MACE
Pooled result
As reported in the abstract
- SGLT-2 inhibitors and GLP-1RAs showed beneficial effects on mortality and MACE vs DPP-4 inhibitors and sulphonylureas
- SGLT-2 inhibitors most effective for hospitalisation for heart failure (HHF) and kidney disease
- Absolute effects of SGLT-2 inhibitors and GLP-1RAs evident for established or high CVD risk but limited for the low-risk subgroup
Original publication
Effects of DPP‐4 inhibitors, GLP‐1 receptor agonists, SGLT‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach. Diabet Med. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →